Using a CSF-1R blocker (Pexidartinib), in the form of hydrogel loaded with Pexidartinib (PLX)-encapsulated nanoparticles, facilitates the local and systemic delivery of anti-programmed cell death protein 1 (anti-PD-1) antibody-conjugated platelets and inhibits tumor recurrence after surgery [68]. Here, PDCD1 is linked to neoplasm.